Functional and structural features of adipokine family

Cytokine

Volumn 61, Issue 1, 2013, Pages 1-14

  Raucci, R ^a   Rusolo, F ^b   Sharma, A ^a   Colonna, G ^a   Castello, G ^b   Costantini, S ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adipokines; Cancer; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; APELIN; CARRIER PROTEIN; CELL PROTEIN; CHEMERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 1; COMPLEMENT FACTOR D; GHRELIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESTATIN; OMENTIN; PROTEIN PAI 1; RESISTIN; RETINOL PROTEIN BINDING 4; SECRETED FRIZZLED RELATED PROTEIN 5; SECRETORY PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

DISEASE ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADIPOKINES; ADIPOSE TISSUE, WHITE; CHEMOKINES; CYTOKINES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NEOPLASMS; OBESITY; PROTEIN STRUCTURE, SECONDARY;

EID: 84869861336     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.036     Document Type: Review

References (117)

1. Siiteri P.K. Adipose tissue as a source of hormones. Am J Clin Nutr 1987, 45:277-282.
2. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
3. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
4. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
5. Frayn K.N., Karpe F., Fielding B.A., Macdonald I.A., Coppack S.W. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003, 27:875-888.
6. Balistreri C.R., Caruso C., Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediat Inflamm 2010, 2010:802078.
7. Redinger R.N. Fat storage and the biology of energy expenditure. Translat Res 2009, 154:52-60.
8. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrin Metab 2000, 11:327-332.
9. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
10. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30.
11. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
12. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
13. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in micelacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
14. Shapiro L., Scherer P.E. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998, 8:335-338.
15. Miele M., Costantini S., Colonna G. Structural and functional similarities between osmotin from nicotiana tabacum seeds and human adiponectin. PLoS ONE 2011, 6:e16690.
16. Rosen B.S., Cook K.S., Yaglom J., Groves D.L., Volanakis J.E., Damm D., et al. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 1989, 244:1483-1487.
17. Volanakis J.E., Narayana S.V. Complement factor D, a novel serine protease. Protein Sci 1996, 5:553-564.
18. De Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52:415-472.
19. Spyroulias G.A., Nikolakopoulou P., Tzakos A., Gerothanassis I.P., Magafa V., Manessi-Zoupa E., et al. Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship. Eur J Biochem 2003, 270:2163-2173.
20. Japp A.G., Cruden N.L., Amer D.A., Li V.K., Goudie E.B., Johnston N.R., et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008, 52:908-913.
21. Castan-Laurell I., Vitkova M., Daviaud D., Dray C., Kovacikova M., Kovacova Z., et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 2008, 158:905-910.
22. Dray C., Knauf C., Daviaud D., Waget A., Boucher J., Buleon M., et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008, 8:437-445.
23. Chun H.J., Ali Z.A., Kojima Y., Kundu R.K., Sheikh A.Y., Agrawal R., et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008, 118:3343-3354.
24. Fan X., Zhou N., Zhang X., Mukhtar M., Lu Z., Fang J., et al. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry 2003, 42:10163-10168.
25. Langelaan D.N., Bebbington E.M., Reddy T., Rainey J.K. Structural insight into G-protein coupled receptor binding by apelin. Biochemistry 2009, 48:537-548.
26. Castaňeda T.R., Tong J., Datta R., Culler M., Tschöp M.H. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010, 31:44-60.
27. Chartrel N., Alvear-Perez R., Leprince J., Iturrioz X., Reaux-Le Goazigo A., Audinot V., et al. Comment on Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on foodintake. Science 2007, 315:766.
28. Annemie V.D., Debby V.D., Valentijn V., Bart D.S., Walter L., Liliane S., et al. Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regul Pept 2009, 156:77-82.
29. Egido E.M., Hernandez R., Marco J., Silvestre R.A. Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regul Pept 2009, 152:61-66.
30. Scrima M., Campiglia P., Esposito C., Gomez-Monterrey I., Novellino E., D'Ursi A.M. Obestatin conformational features: a strategy to unveil obestatin's biological role?. Biochem Biophys Res Commun 2007, 363:500-505.
31. Wong G.W., Wang J., Hug C., Tsao T.S., Lodish H.F. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci 2004, 101:10302-10307.
32. Kishore U., Reid K.B. C1q: structure, function, and receptors. Immunopharmacology 2000, 49:159-170.
33. Jeon J.H., Kim K.Y., Kim J.H., Baek A., Cho H., Lee Y.H., et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008, 22:1502-1511.
34. Wittamer V., Franssen J.D., Vulcano M., Mirjolet J.F., Le Poul E., Migeotte I., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fl uids. J Exp Med 2003, 198:977-985.
35. Ernst M.C., Sinal C.J. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010, 21:660-667.
36. Allen S.J., Zabel B.A., Kirkpatrick J., Butcher E.C., Nietlispach D., Handel T.M. NMR assignment of human chemerin, a novel chemoattractant. Biomol NMR Assign 2007, 1:171-173.
37. Bastard J.P., Lagathu C., Caron M., Capeau J. Point-counterpoint: interleukin- 6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007, 102:821-822.
38. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
39. Pedersen B.K., Fischer C.P. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 2007, 10:265-271.
40. Xu G.Y., Yu H.A., Hong J., Stahl M., McDonagh T., Kay L.E., et al. Solution structure of recombinant human interleukin-6. J Mol Biol 1997, 268:468-481.
41. Somers W., Stahl M., Seehra J.S. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J 1997, 16:989-997.
42. Boisvert W.A. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004, 14:161-165.
43. Frangogiannis N.G. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res 2004, 53:585-595.
44. Eigenbrot C., Lowman H.B., Chee L., Artis D.R. Structural change and receptor binding in a chemokine mutant with a rearranged disulfide: X-ray structure of E38C/C50AIL-8 at 2A resolution. Proteins 1997, 27:556-566.
45. Ahima R.S., Qi Y., Singhal N.S., Jackson M.B., Scherer P.E. Brain adipocytokine action and metabolic regulation. Diabetes 2006, 55:S145-S154.
46. Aspden R.M. Obesity punches above its weight in osteoarthritis. Nat Rev Rheumatol 2011, 7(1):65-68.
47. Zhang F., Basinski M.B., Beals J.M., Briggs S.L., Churgay L.M., Clawson D.K., et al. Crystal structure of the obese protein leptin-E100. Nature 1997, 387:206-209.
48. Wang Y., Lam K.S., Kraegen E.W., Sweeney G., Zhang J., Tso A.W., et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007, 53:34-41.
49. Guo H., Jin D., Zhang Y., Wright W., Bazuine M., Brockman D.A., et al. Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes 2010, 59:1376-1385.
50. Goetz D.H., Willie S.T., Armen R.S., Bratt T., Borregaard N., Strong R.K. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000, 39:1935-1941.
51. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
52. Martinovic I., Abegunewardene N., Seul M., Vosseler M., Horstick G., Buerke M., et al. Elevated monocyte chemoattractant protein- 1 serum levels in patients at risk for coronary artery disease. Circ J 2005, 69:1484-1489.
53. Lubkowski J., Bujacz G., Boque L., Domaille P.J., Handel T.M., Wlodawer A. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat Struct Biol 1997, 4:64-69.
54. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
55. Fu M., Gong D.W., Damcott C., Sabra M., Yang R.Z., Pollin T.I., et al. Systematic analysis of omentin 1 and omentin 2 on 1q23 as candidate genes for type 2 diabetes in the old order amish. Diabetes 2004, 53:A59.
56. Bastelica D., Morange P., Berthet B., Borghi H., Lacroix O., Grino M., et al. Stromal cells are the main plasminogen activator inhibitor- 1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002, 22:173-178.
57. Alessi M.C., Poggi M., Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007, 18:240-245.
58. Oishi K., Ohkura N., Wakabayashi M., Shirai H., Sato K., Matsuda J., et al. CLOCK is involved in obesity-induced disordered fibrinolysis in ob/ob mice by regulating PAI-1 gene expression. J Thromb Haemost 2006, 4:1774-1780.
59. Stout T.J., Graham H., Buckley D.I., Matthews D.J. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 2000, 39:8460-8469.
60. Qi Y., Nie Z., Lee Y.S., Singhal N.S., Scherer P.E., Lazar M.A., et al. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006, 55:3083-3090.
61. Steppan C.M., Wang J., Whiteman E.L., Birnbaum M.J., Lazar M.A. Activation of SOCS-3 by resistin. Mol Cell Biol 2005, 25:1569-1575.
62. Patel S.D., Rajala M.W., Rossetti L., Scherer P.E., Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004, 304:1154-1158.
63. Qatanani M., Szwergold N.R., Greaves D.R., Ahima R.S., Lazar M.A. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009, 119:531-539.
64. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
65. Kloting N., Graham T.E., Berndt J., Kralisch S., Kovacs P., Wason C.J., et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007, 6:79-87.
66. Ribel-Madsen R., Friedrichsen M., Vaag A., Poulsen P. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes 2009, 58(1):54-60.
67. Greene L.H., Chrysina E.D., Irons L.I., Papageorgiou A.C., Acharya K.R., Brew K. Role of conserved residues in structure and stability: tryptophans of human serum retinol-binding protein, a model for the lipocalin superfamily. Protein Sci 2001, 10:2301-2316.
68. Naylor H.M., Newcomer M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 1999, 38:2647-2653.
69. Ouchi N., Higuchi A., Ohashi K., Oshima Y., Gokce N., Shibata R., et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010, 329:454-457.
70. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
71. Maury E., Noel L., Detry R., Brichard S.M. In vitro hyper-responsiveness to TNF-{alpha} contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 2009, 94:1393-1400.
72. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
73. Ohta H., Wada H., Niwa T., Kirii H., Iwamoto N., Fujii H., et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180:11-17.
74. Swardfager W., Lanctôt K., Rothenburg L., Wong A., Cappell J., Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010, 68:930-941.
75. Eck M.J., Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6A resolution. Implications for receptor binding. J Biol Chem 1989, 264:17595-17605.
76. El-Mesallamy H.O., Kassem D.H., El-Demerdash E., Amin A.I. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011, 60:63-70.
77. Lago F., Dieguez C., Gómez-Reino J., Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325.
78. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005, 102:10610-10615.
79. Youn B.S., Klöting N., Kratzsch J., Lee N., Park J.W., Song E.S., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
80. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci 2005, 102:10610-10615.
81. Garten A., Petzold S., Korner A., Imai S.I., Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009, 20:130-138.
82. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
83. Khan J.A., Tao X., Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 2006, 13:582-588.
84. Lew E.A., Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chron Dis 1979, 32:563-576.
85. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335:1134.
86. Bergstrom A., Pisani P., Tenet V., Wolk A., Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001, 91:421-430.
87. Paz-Filho G., Lim E.L., Wong M.-L., Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci 2011, 16:1634-1650.
88. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
89. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Brit J Cancer 2006, 94:1221-1225.
90. Sorli S.C., Le Gonidec S., Knibiehler B., Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007, 26:7692-7699.
91. Melgarejo E., Medina M.A., Sánchez-Jiménez F., Urdiales J.L. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 2009, 41:998-1001.
92. Lin W., Chen Y.L., Jiang L., Chen J.K. Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clin Lab 2011, 57:879-885.
93. Qu X., Han L., Wang S., Zhang Q., Yang C., Xu S., et al. Detection of chemerin and it's clinical significance in peripheral blood of patients with lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12:1174-1177.
94. Heikkilä K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008, 44:937-945.
95. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391.
96. Garofalo C., Surmacz E. Leptin and Cancer. J Cell Physiol 2006, 207:12-22.
97. Bolignano D., Donato V., Lacquaniti A., Fazio M.R., Bono C., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010, 28810-28816.
98. Zheng L., Weng M., Qi M., Qi T., Tong L., Hou X., et al. Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J Cancer Res Clin Oncol 2012, 138:163-172.
99. Al-Harithy R.N., Al-Ghafari A.B. Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J 2010, 31:495-500.
100. Karapanagiotou E.M., Tsochatzis E.A., Dilana K.D., Tourkantonis I., Gratsias I., Syrigos K.N. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung cancer 2008, 61:391-397.
101. Lorkova L., Pospisilova J., Lacheta J., Leahomschi S., Zivny J., Cibula D., et al. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep 2012, 27:318-324.
102. Wang D.D., Zhao Y.M., Wang L., Ren G., Wang F., Xia Z.G., et al. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection. J Cancer Res Clin Oncol 2011, 137:651-658.
103. Aguilera O., Muñoz A., Esteller M., Fraga M.F. Epigenetic alterations of the Wnt/beta-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 2007, 7:13-21.
104. Su H.Y., Lai H.C., Lin Y.W., Liu C.Y., Chen C.K., Chou Y.C., et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010, 127:555-567.
105. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010, 10:323.
106. Bi T.Q., Che X.M. Nampt/PB Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010, 10:119-125.
107. Ahmet A., Blaser S., Stephens D., Guger S., Rutkas J.T., Hamilton J. Weight gain in craniopharyngioma-a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006, 19:121-127.
108. Uemura H., Ishiguro H., Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008, 15:19-26.
109. Andreasen P.A. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 2007, 8:1030-1041.
110. Scardoni G., Petterlini M., Laudanna C. Analyzing biological network parameters with CentiScaPe. Bioinformatics 2009, 25:2857-2859.
111. Kohl M., Wiese S., Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 2011, 696:291-303.
112. Gómez D., González-Arangüena E., Manuel C., Owen G., del Pozo M., Tejada J. Centrality and power in social networks: a game theoretic approach. Math Soc Sci 2003, 46:27-54.
113. Yu H., Kim P.M., Sprecher E., Trifonov V., Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007, 3:e59.
114. Brandes U. A faster algorithm for betweenness centrality. J Math Sociol 2001, 25:163-177.
115. Sharma A., Gautam V., Costantini S., Paladino A., Colonna G. Interactomic and pharmacological insights on human Sirt-1. Front Exp Pharmacol Drug Discov 2012, 3:40.
116. Costantini S, Sharma A, Colonna G. The value of the cytokinome profile. Inflammatory diseases - a modern perspective; 2011 [ISBN: 978-953-307-444-3].
117. Costantini S., Capone F., Guerriero E., Marfella R., Sorice A., Maio P., et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS ONE 2012, 7:e39486.